Want to see EW full AI Analyst Report?
EW Stock Chart & Stats
$80.99
$0.80(1.09%)
At close: 4:00 PM EST
$80.99
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$72.30 - $96.29
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.69M
Market Cap
$49.36B
Enterprise Value$43.53K
Total Cash (Recent Filing)$3.67B
Total Debt (Recent Filing)$702.90M
Price to Earnings (P/E)45.4
Beta0.59
Next Earnings
Jul 23, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding575,800,000
10 Day Avg. Volume4,367,725
30 Day Avg. Volume4,693,147
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)4.82
Price to Sales (P/S)8.22
P/FCF Ratio37.34
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$100.81Price Target Upside24.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)3.01
Revenue Forecast (FY)$6.76B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsVery high gross and healthy operating/net margins indicate durable pricing power and cost structure advantages in medical devices. These margins support sustained cash generation to fund R&D, clinical trials and product rollouts, strengthening competitive position and long-term profitability.
Conservative Balance SheetExtremely low leverage provides financial flexibility to invest in new indications, absorb cyclical volumes, and pursue M&A without stressing liquidity. Modest debt reduces bankruptcy risk and supports consistent capital allocation while preserving strategic optionality over multiple market cycles.
Recurring Consumables And Positive FCFRecurring revenues from single-use sensors and disposables create annuity-like cash streams tied to hospital utilization. Combined with multi-hundred-million FCF, this drives durable cash generation that funds ops and innovation, lessening reliance on external financing for growth initiatives.
Bears Say
Subdued Revenue GrowthTop-line growth has been modest and uneven, which constrains long-term earnings leverage. In a mature structural heart market, limited organic growth increases dependence on share gains, new indications, or M&A to materially expand revenue, making sustained EPS growth harder to achieve.
Weaker Cash ConversionDeclining FCF and subpar cash conversion reduce the firm's internal funding capacity. Lower conversion heightens sensitivity to working capital swings and could constrain funding for clinical programs or capital allocation if trends persist, despite headline positive FCF levels.
Expanded Equity Incentive CapacityA materially larger share pool improves talent retention but raises the risk of dilution if grants are fully exercised. Increased issuance capacity can pressure per-share metrics over time and represent an overhang on EPS growth if not offset by commensurate revenue or margin expansion.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences Corp.’s price range in the past 12 months?
Edwards Lifesciences Corp. lowest stock price was $72.30 and its highest was $96.29 in the past 12 months.
What is Edwards Lifesciences Corp.’s market cap?
Edwards Lifesciences Corp.’s market cap is $49.36B.
When is Edwards Lifesciences Corp.’s upcoming earnings report date?
Edwards Lifesciences Corp.’s upcoming earnings report date is Jul 23, 2026 which is in 4 days.
How were Edwards Lifesciences Corp.’s earnings last quarter?
Edwards Lifesciences Corp. released its earnings results on Apr 23, 2026. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.729 by $0.051.
Is Edwards Lifesciences Corp. overvalued?
According to Wall Street analysts Edwards Lifesciences Corp.’s price is currently Undervalued.
Does Edwards Lifesciences Corp. pay dividends?
Edwards Lifesciences Corp. does not currently pay dividends.
What is Edwards Lifesciences Corp.’s EPS estimate?
Edwards Lifesciences Corp.’s EPS estimate is 0.74.
How many shares outstanding does Edwards Lifesciences Corp. have?
Edwards Lifesciences Corp. has 575,800,000 shares outstanding.
What happened to Edwards Lifesciences Corp.’s price movement after its last earnings report?
Edwards Lifesciences Corp. reported an EPS of $0.78 in its last earnings report, beating expectations of $0.729. Following the earnings report the stock price went up 5.557%.
Which hedge fund is a major shareholder of Edwards Lifesciences Corp.?
Currently, no hedge funds are holding shares in EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.81 (24.48% Upside)
$100.81 (24.48% Upside)
Blogger Sentiment
Neutral
EW Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.53%
12-Months-Change
Fundamentals
Return on Equity
10.55%
Trailing 12-Months
Asset Growth
2.30%
Trailing 12-Months
Company Description
Edwards Lifesciences Corp.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
EW Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
EW Stock 12 Month Forecast
Average Price Target
$100.81
▲(24.48% Upside)
Technical Analysis
Ownership Overview
0.24% Insiders
25.51% Mutual Funds
1.77% Other Institutional Investors
46.15% Public Companies and
Individual Investors